Menu
FDA DECISION ·
Anktiva + BCG
nogapendekin alfa inbakicept-pmln with Bacillus Calmette–Guérin · Altor BioScience / ImmunityBio
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). This expansion adds high-grade papillary-only tumors to the prior carcinoma-in-situ population.
LAMPGEN ANALYSIS
Why it matters
The expansion reaches patients with high-grade papillary-only disease, whose eligibility previously depended on the presence of carcinoma in situ. FDA discussed how aggressive papillary and in-situ tumors can overlap.
What research teams should watch
Record whether pathology shows papillary-only disease or carcinoma in situ and verify prior BCG exposure and response. Preserve that distinction when reporting outcomes across the expanded population.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
BCG-unresponsive non-muscle-invasive bladder cancerPRIMARY RECORDS